Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies

Autor: Bollineni, Vikram R., Koole, Michel J.B., Pruim, Jan, Brouwer, Charlotte L., Wiegman, Erwin M., Groen, Harry J.M., Vlasman, Renske, Halmos, Gyorgy B., Oosting, Sjoukje F., Langendijk, Johannes A., Widder, Joachim, Steenbakkers, Roel J.H.M.

Publikováno v: In Radiotherapy and Oncology November 2014 113(2):198-203

Periodontitis and cardiovascular diseases: Consensus report

Autor: Sanz, M. Marco del Castillo, A. Jepsen, S. Gonzalez-Juanatey, J.R. D'Aiuto, F. Bouchard, P. Chapple, I. Dietrich, T. Gotsman, I. Graziani, F. Herrera, D. Loos, B. Madianos, P. Michel, J.B. Perel, P. Pieske, B. Shapira, L. Shechter, M. Tonetti, M. Vlachopoulos, C. Wimmer, G.

Background: In Europe cardiovascular disease (CVD) is responsible for 3.9 million deaths (45% of deaths), being ischaemic heart disease, stroke, hypertension (leading to heart failure) the major cause of these CVD related deaths. Periodontitis is als

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1b9ed61e8bfff0ee3366af4c18e13c9d
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2990012

Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice

Autor: Arnal, J.F ^*, Castano, C, Maupas, E, Mugniot, A, Darblade, B, Gourdy, P, Michel, J.B, Bayard, F

Publikováno v: In Atherosclerosis 2001 155(2):291-295

Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm

Autor: Montero, R.R., Perez-Saez, J.M., Cerro-Pardo, I., Martinez-Lopez, D., Nuñez, E., Maller, S., Gutierrez-Muñoz, C., Mendez-Barbero, N., Escola-Gil, J.C., Michel, J.B., Vazquez, J., Blanco-Colio, L.M., Rabinovich, G.A., Martin-Ventura, J.L.

Publikováno v: In Atherosclerosis August 2021 331:e96-e97

Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition

Autor: Kerner, Gerald S.M.A., Koole, Michel J.B., Bongaerts, Alphons H.H., Pruim, Jan, Groen, H. J.M., Van Dongen, G., Caldenhoven, E., Coupé, V. M.H., Fischer, A., Perk, L., Van Herk, M., Elsinga, P. H., Lambin, P., Brakenhoff, R. H., Boellaard, R., Uyl, C., Van Criekinge, W.

Publikováno v: PLoS ONE, 11(5):e0149955. Public Library of Science
PLOS ONE, 11(5):e0149955. Public Library of Science
PLoS ONE, 11(5):e0149955. PUBLIC LIBRARY SCIENCE
PLoS ONE
Kerner, G S M A, Koole, M J B, Bongaerts, A H H, Pruim, J, Groen, H J M, Van Dongen, G, Caldenhoven, E, Coupé, V M H, Fischer, A, Groen, H J M, Perk, L, Van Herk, M, Elsinga, P H, Lambin, P, Brakenhoff, R H, Boellaard, R, Uyl, C, Van Criekinge, W & CTMM Air Force Consortium 2016, ' Total body metabolic tumor response in ALK positive non-small cell lung cancer patients treated with ALK inhibition ', PLoS ONE, vol. 11, no. 5, e0149955 . https://doi.org/10.1371/journal.pone.0149955
PLoS ONE, Vol 11, Iss 5, p e0149955 (2016)

Background: In ALK-positive advanced NSCLC, crizotinib has a high response rate and effectively increases quality of life and survival. CT measurement of the tumor may insufficiently reflect the actual tumor load changes during targeted therapy with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a1aec94cc720aa5705fa32fc2e07917
https://doi.org/10.1371/journal.pone.0149955